GLOW is a peptide blend combining GHK-Cu, BPC-157, and TB-500, primarily discussed for skin rejuvenation and wound healing. Community reports show people most often use around 2 mg per day without a specified schedule, though no clinician-recommended dosing protocols exist. Nausea or GI discomfort has been occasionally reported, while injection-site reactions and other common peptide side effects have not surfaced consistently in user reports.
Data last updated
Measured on 5 of 6 axes
Evidence shape
The evidence for GLOW is limited, with nine human studies focused on treatment and diagnostic or mechanistic research but no completed clinical trials. It maps to three indications, though only treatment studies have multiple explorations, while diagnostic work remains thin and preclinical data exist only in animals. No registered trials have been posted, leaving efficacy unverified at scale.
Efficacy signal
Completed studies are present, but primary-endpoint pass/fail classification is not yet clean enough to score. These are the currently projected indication-level signals.
Treatment studies
8 studies
Diagnostic & mechanistic studies
1 study
No completed study rows are available for endpoint scoring yet.
Human evidence
Lower-tier support
Published literature
Standalone PubMed / Europe PMC publications matched to this peptide and deduped by identifier. Trial records and animal / in-vitro rows are surfaced above; these are the human-relevant papers behind them.
Source data
Clinical research side effects
Clinical safety table not projected yet.
Anecdotal side effects
price offers can be sorted by column · 19 out-of-stock offers not shown
Some links are affiliate links. This never affects our rankings or inclusion.
How GLOW is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.
In the research‑trial tier for GLOW, no reliable dosing information could be extracted from the eight identified human studies; amount, frequency, and cycling are not specified.
The clinician practice tier lists a dose of 0 mcg, and provides no frequency, timing, route, or cycle information for this tier.
Users report doses ranging from 400 mcg to 15 mg, with a typical amount of 2 mg administered subcutaneously; two of six reports describe daily dosing, while another two follow a 5‑days‑on/2‑days‑off cycle.